|
|
|
|
|
|
|
|
|
|
Blogger's Note: not specific to ovarian cancer
Insight: Training immune system to fight cancer comes of age | Reuters
".....While extending life is the gold standard, most cancer drug trials have been deemed successful if tumors shrink or if a treatment can demonstrate a delay in tumor growth or in worsening of the disease, known as progression-free survival (PFS).
But Provenge and Yervoy have extended survival without necessarily impacting PFS or tumor shrinkage in many cases.
"Overall survival is the accurate indicator. Tumors may look bigger because they are filled with immune cells, so they appear worse," said Wolchok. "We've proposed a new set of response criteria to try to incorporate some of this biology.".......
0 comments :
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.